

Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease

著者別名	古川 宏, 土屋 尚之
journal or publication title	BMC musculoskeletal disorders
volume	18
page range	21
year	2017-01
権利	(C) The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
URL	http://hdl.handle.net/2241/00148408

doi: 10.1186/s12891-017-1389-4

RESEARCH ARTICLE

Open Access



Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease

Shomi Oka^{1,2}, Hiroshi Furukawa^{1,2*}, Kota Shimada^{3,4}, Atsushi Hashimoto³, Akiko Komiya², Naoshi Fukui², Naoyuki Tsuchiya¹ and Shigeto Tohma²

Abstract

Background: Interstitial lung disease (ILD) is frequently associated with rheumatoid arthritis (RA), and is designated RA-associated ILD (RA-ILD). RA-ILD has a large impact on the prognosis of RA. Here, we investigated the micro RNAs (miRNAs) profiles to determine whether they may be useful for diagnosing RA-ILD.

Methods: RNA was isolated from plasma samples and cDNA was synthesized. Real-time RT-PCR analysis was performed to evaluate 752 miRNA expression profiles in plasma pools from RA patients with or without RA-ILD. Sixteen selected miRNA levels were analyzed in individual plasmas from 64 RA patients with or without RA-ILD.

Results: Expression levels of hsa-miR-214-5p (mean relative expression level \pm standard deviation, 8.1 ± 28.2 in RA with ILD, 0.2 ± 0.9 in RA without ILD, $P = 0.0156$) and hsa-miR-7-5p (56.2 ± 260.4 in RA with ILD, 4.7 ± 11.8 in RA without ILD, $P = 0.0362$) were higher in RA patients with RA-ILD than in those without. The values of miRNA index (214, 7) generated from hsa-miR-214-5p and hsa-miR-7-5p for ILD were significantly elevated in RA patients with RA-ILD compared with those without (0.122 ± 0.332 in RA with ILD, 0.006 ± 0.013 in RA without ILD, $P = 0.0010$). The area under the curve value of the receiver operating characteristic curve for the miRNA index (214, 7) was 0.740.

Conclusions: To the best of our knowledge, this is the first report of miRNA profiles in RA-ILD. The expression levels of hsa-miR-214-5p and hsa-miR-7-5p were increased in RA with ILD.

Keywords: miRNA profile, Rheumatoid arthritis, Interstitial lung disease, Biological marker

Background

Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease with bone and joint destruction. It is well known that interstitial lung disease (ILD) is frequently associated with RA [1]. Although nonspecific interstitial pneumonia (NSIP) pattern is predominantly observed in collagen disease patients with ILD, usual interstitial pneumonia (UIP) pattern is often observed in RA-associated ILD (RA-ILD) patients [2]. The prognosis of idiopathic interstitial pneumonia patients with UIP pattern was reported to be worse than

those with NSIP [3]. The presence of ILD influences the prognosis of RA [4, 5]. Krebs von den lungen-6 (KL-6) and surfactant protein-D (SP-D) have been used as biomarkers for ILD, but have low sensitivity for the detection of RA-ILD [6, 7]. Thus, better biomarkers for the early screening of RA-ILD are eagerly expected.

Micro RNAs (miRNAs) are small non-coding RNAs with approximate 22 nucleotide length and are stably detected in plasma or serum. It is widely known that miRNAs modulate the expression of protein-coding genes at the post-transcription level and play important roles in cell activation, proliferation, differentiation, or death. Dysregulation of miRNAs in the circulation was detected in the patients with cancer or other diseases and circulating miRNAs could be potential biomarkers for various diseases [8–10]. Some miRNAs in the circulation were also dysregulated in inflammatory diseases, such as RA

* Correspondence: furukawa-ky@umin.org

¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan

²Clinical Research Center for Allergy and Rheumatology, Sagami Hospital, National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagamihara 252-0392, Japan

Full list of author information is available at the end of the article



[11, 12], inflammatory bowel diseases [13], or idiopathic pulmonary fibrosis (IPF) [14, 15], though the impact of the circulating miRNA in inflammatory diseases does not reach to that in cancer. The expression levels of hsa-miR-132, hsa-miR-24, and hsa-miR-125a-5p were altered in plasma from RA patients [12, 16]. The expression levels of hsa-miR-21 were increased in sera from IPF patients [14, 15, 17]. However, few studies have focused on circulating miRNA profiles of RA-ILD. The present study investigated circulating miRNA profiles of RA-ILD to determine whether they may be useful for diagnosing RA-ILD.

Methods

Patients

Sixty four Japanese patients with RA were recruited at Sagamihara Hospital. ILD was diagnosed from computed tomography (CT) findings by two physicians specializing in RA-ILD. RA patients were categorized from A to Z, based on the Sagamihara Criteria [1]. RA cases in categories A to D were RA with ILD [ILD(+)]RA and those in G and H were RA without ILD [ILD(-)]RA. This study included RA cases in categories A [Findings consistent with ILD were observed in high resolution CT (HRCT) images (length of shorter diameter of the lesion was ≥ 2 cm in a transverse section)] or H [HRCT images were normal] [1]. RA patients with ILD were further diagnosed with one of the two patterns of UIP or NSIP, based on the predominant CT findings: UIP, irregular linear opacities and honeycombing; NSIP, bilateral ground-glass attenuation patterns predominantly in subpleural and basal regions [2, 18, 19]. Plasma samples from the 64 RA patients with or without ILD were collected and these individual plasma samples were analyzed for miRNA expression profiles. Blood samples were taken in tubes with ethylenediaminetetraacetic acid dipotassium salt (Terumo, Tokyo, Japan) and kept in room temperature before separation. Plasma was separated by centrifugation at $1500 \times g$ for 10 min, and then stored at -80 °C until analysis. All patients fulfilled the American College of Rheumatology criteria for RA [20]. This study was reviewed and approved by Sagamihara Hospital Research Ethics Committee and University of Tsukuba Research Ethics Committee. Written informed consent was obtained from all study participants. This study was conducted in accordance with the principles expressed in the Declaration of Helsinki.

MiRNA analysis

RNA was isolated from 200 μ l plasma samples using miRCURY RNA Isolation kit Biofluids (Exiqon, Vedbaek, Denmark) and complementary DNA (cDNA) was synthesized with miRCURY LNA Universal cDNA Synthesis kit II (Exiqon). Real-time RT-PCR analysis was performed to

evaluate miRNA expression in the plasma pool from 17 RA patients with RA-ILD or the pool from 17 RA patients without ILD, using Human miRNome microRNA PCR Panel I + II (Exiqon), ExiLent SYBR Green master mix (Exiqon), and LightCycler 480 System II (Roche, Basel, Switzerland). Thermal cycling conditions consisted of initial denaturation at 95 °C for 10 min, followed by 45 cycles of 95 °C for 10 s followed by 60 °C for 1 min. Interplate calibration was conducted by the subtraction of the average C_T values of UniSP3 probe of the plate. The levels of miRNA among plasma samples were normalized to the average expression of five circulating miRNAs; hsa-miR-425-5p, hsa-miR-423-5p, hsa-miR-103a-3p, hsa-miR-191-5p, hsa-miR-93-5p. The amount of miRNA was quantified using comparative C_T method. The two pooled plasma of ILD(+)]RA or ILD(-)]RA were screened for the miRNA profiling. The data obtained from the microRNA PCR panels were deposited in Gene Expression Omnibus of National Center for Biotechnology Information and are accessible by accession number GSE88899. The PCR panel contains 752 probes for human miRNAs. Potential miRNA markers were selected for real-time RT-PCR analysis of miRNAs in individual patient plasma, based on the PCR panel data; eight miRNAs with higher absolute $\Delta\Delta C_T$ values (The $\Delta\Delta C_T$ values of these eight miRNAs were higher than 3.12) were selected when the samples with undefined C_T values of wells for detection of gene of interest were eliminated for the selection. Other eight miRNAs with higher absolute $\Delta\Delta C_T$ values (The $\Delta\Delta C_T$ values of these eight miRNAs were higher than 5.10) were selected when the undefined C_T values were substituted by 40. Thus, sixteen miRNAs were selected for the individual analysis.

Pick-&-Mix microRNA PCR Panel (Exiqon), ExiLent SYBR Green master mix (Exiqon), and Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA) were employed for the detection of miRNAs in each individual plasma sample from 64 RA patients with or without RA-ILD that include the above-mentioned 34 RA patients in the screening. The same thermal cycling condition was used. The expression levels of miRNAs in the samples with undefined C_T values were define to be 0. The levels of miRNA among plasma samples were normalized to the average expression of three circulating miRNAs; hsa-miR-103a-3p, hsa-miR-191-5p, hsa-miR-93-5p. Relative expression levels of miRNAs in plasma were calculated with comparative C_T method.

Statistical analysis

Differences in patient characteristics were analyzed by Mann-Whitney's U test or Fisher's exact test using 2X2 contingency tables. Mann-Whitney's U test was conducted for the comparison of miRNA expression levels. Multiple linear regression analysis was performed to

develop miRNA index for ILD in RA from miRNA levels. Correction for multiple testing was performed by calculating false discovery rate Q-value [21]. Target genes for the miRNAs were predicted using target prediction algorithm at miRDB (<http://mirdb.org>) [22].

Results

Clinical features of the RA patients

Characteristics of the RA patients are shown in Table 1. Mean age, percentage of males, KL-6, SP-D, and disease activity score 28 (DAS28) in ILD(+)RA were higher than in ILD(-)RA. The percentage of administration of biological disease-modifying anti-rheumatic drugs (DMARDs) in ILD(+)RA were lower than in ILD(-)RA. Mean age, percentage of males, KL-6, and SP-D in RA with UIP pattern [UIP(+)]RA were higher than in ILD(-)RA. The percentage of administration of biological DMARDs in UIP(+)]RA were lower than in ILD(-)RA. Mean age, disease duration, KL-6, SP-D, DAS28, and DAS28CRP in RA with ILD of NSIP pattern [NSIP(+)]RA were higher than in ILD(-)RA.

MiRNA expression profiles of RA patients with or without ILD

Pooled plasma miRNA profiles were compared between ILD(+)RA and ILD(-)RA groups (Additional file 1: Table

S1). Of 752 tested miRNA, 530 miRNAs were up-regulated and 217 miRNAs were down-regulated in ILD(+)RA. Sixteen miRNAs with higher absolute $\Delta\Delta Ct$ values were selected for further analysis on the individual plasmas, as described in Materials and methods (indicated in red, Additional file 1: Table S1).

Sixteen miRNAs as potential biomarkers (hsa-miR-29c-3p, hsa-miR-154-5p, hsa-miR-543, hsa-miR-214-5p, hsa-miR-382-3p, hsa-let-7g-3p, hsa-miR-9-5p, hsa-miR-370-3p, hsa-miR-221-5p, hsa-miR-483-5p, hsa-miR-7-5p, hsa-miR-376b-3p, hsa-miR-487b-3p, hsa-let-7f-1-3p, hsa-miR-500a-5p, hsa-miR-582-5p) were selected for further analysis of miRNAs in individual patient plasma. The 16 miRNAs were also compared between the ILD(+)RA and ILD(-)RA using the real-time RT-PCR method (Table 2 and Additional file 2: Figure S1). The results show a tendency for the expression levels of hsa-miR-214-5p and hsa-miR-7-5p to be increased in the ILD(+)RA group (Fig. 1a and b). Although, male percentage is higher in the ILD(+)RA group, the expression levels of 16 selected miRNAs were not different between male and female in the ILD(+)RA group (Additional file 3: Table S2). The effects of the age on the expression levels of some miRNAs were detected (Additional file 4: Table S3). The effects of the DAS28 on the expression

Table 1 Characteristics of the RA patients

		ILD(+)]RA	UIP(+)]RA	NSIP(+)]RA	ILD(-)]RA	ILD(+)]RA <i>P</i>	UIP(+)]RA <i>P</i>	NSIP(+)]RA <i>P</i>
Number		32	18	14	32			
Age	year	70.2 (7.4)	70.6 (8.0)	69.6 (6.8)	57.7 (13.8)	0.0002	0.0013	0.0043
male number	n (%)	11 (34.4)	9 (50.0)	2 (14.3)	2 (6.3)	*0.0109	*0.0007	*0.5745
Disease duration	year	15.5 (12.6)	12.8 (12.2)	18.9 (12.7)	10.6 (7.4)	0.1830	0.8953	0.0116
Steinbrocker stage III and IV	n (%)	18 (56.3)	9 (50.0)	9 (64.3)	21 (65.6)	*0.6088	*0.3701	*1.0000
Smoker or past smoker	n (%)	10 (33.3)	7 (38.9)	3 (25.0)	10 (32.3)	*1.0000	*0.7581	*0.7272
Rheumatoid factor positive	n (%)	30 (93.8)	17 (94.4)	13 (92.9)	27 (84.4)	*0.4258	*0.3991	*0.6506
Anti-citrullinated peptide antibody positive	n (%)	31 (96.9)	18 (100.0)	13 (92.9)	31 (96.9)	*1.0000	*1.0000	*0.5208
KL-6	U/ml	1096.4 (853.7)	1086.2 (828.4)	1108.8 (914.9)	315.3 (257.9)	2.44×10^{-7}	2.97×10^{-6}	0.0001
SP-D	ng/ml	194.1 (244.7)	177.3 (192.3)	214.5 (303.0)	46.0 (37.5)	2.48×10^{-5}	0.0008	0.0001
DAS28		4.0 (1.2)	3.7 (1.3)	4.3 (0.9)	3.1 (1.2)	0.0040	0.0793	0.0021
DAS28-CRP		3.0 (1.3)	2.6 (1.4)	3.4 (1.0)	2.4 (1.0)	0.0500	0.5855	0.0035
NSAIDs administration	n (%)	13 (41.9)	7 (38.9)	6 (46.2)	15 (48.4)	*0.7989	*0.5647	*1.0000
Corticosteroid administration	n (%)	26 (83.9)	14 (77.8)	12 (92.3)	25 (80.6)	*1.0000	*1.0000	*0.6542
DMARDs administration	n (%)	24 (77.4)	14 (77.8)	10 (76.9)	30 (96.8)	*0.0529	*0.0542	*0.0706
sDMARDs administration	n (%)	19 (61.3)	11 (61.1)	8 (61.5)	19 (61.3)	*1.0000	*1.0000	*1.0000
bDMARDs administration	n (%)	10 (32.3)	5 (27.8)	5 (38.5)	22 (71.0)	*0.0048	*0.0066	*0.0874

Average values or numbers of each group are shown. Standard deviations or percentages are shown in parenthesis. Differences were tested by Mann-Whitney's U test or Fisher's exact test using 2×2 contingency tables

RA rheumatoid arthritis, ILD interstitial lung disease, UIP Usual interstitial pneumonia, NSIP Nonspecific interstitial pneumonia, ILD(+)]RA RA with ILD, UIP(+)]RA RA with ILD of UIP pattern, NSIP(+)]RA RA with ILD of NSIP pattern, ILD(-)]RA RA without ILD, KL-6 krebs von den lungen-6, SP-D Surfactant protein-D, DAS28 disease activity score 28, NSAIDs non-steroidal anti-inflammatory drug, DMARD disease-modifying anti-rheumatic drug, sDMARD synthetic DMARD, bDMARD biological DMARD

*Fisher's exact test was employed

Table 2 miRNA profiles of the RA patients with or without ILD

miRNA					ILD(+)/RA		UIP(+)/RA		NSIP(+)/RA	
	ILD(+)/RA	UIP(+)/RA	NSIP(+)/RA	ILD(-)/RA	P	FDR Q	P	FDR Q	P	FDR Q
hsa-miR-29c-3p	28.7 (92.4)	45.9 (121.6)	6.7 (10.4)	2.9 (2.5)	0.1772	0.6025	0.0499	0.1698	0.9334	0.9334
hsa-miR-154-5p	17.9 (59.1)	24.6 (76.8)	9.3 (21.3)	2.0 (2.8)	0.9238	0.9815	0.5331	0.7294	0.3604	0.7416
hsa-miR-543	11.0 (35.9)	14.8 (46.6)	6.1 (13.9)	1.4 (1.4)	0.4386	0.6213	0.8633	0.9173	0.1145	0.6099
hsa-miR-214-5p	8.1 (28.2)	13.6 (37.0)	1.0 (3.2)	0.2 (0.9)	0.0156	0.1322	0.0076	0.0643	0.1697	0.6099
hsa-miR-382-3p	10.9 (41.5)	14.8 (52.9)	5.8 (19.9)	0.9 (1.7)	0.4279	0.6213	0.9473	0.9473	0.1794	0.6099
hsa-let-7g-3p	29.1 (107.3)	50.3 (141.1)	1.9 (3.7)	3.3 (5.3)	0.6098	0.7974	0.5578	0.7294	0.1095	0.6099
hsa-miR-9-5p	5.8 (18.5)	9.1 (24.2)	1.5 (4.2)	0.9 (2.6)	0.8510	0.9815	0.7724	0.8753	0.4947	0.7416
hsa-miR-370-3p	12.2 (57.4)	18.2 (76.3)	4.5 (11.1)	0.3 (0.4)	0.8766	0.9815	0.3648	0.6202	0.4734	0.7416
hsa-miR-221-5p	17.1 (53.1)	26.6 (68.7)	5.0 (16.6)	0.7 (1.2)	0.3227	0.6213	0.0461	0.1698	0.5235	0.7416
hsa-miR-483-5p	80.7 (331.8)	130.5 (440.8)	16.6 (24.4)	14.3 (33.9)	0.2827	0.6213	0.2330	0.4951	0.6161	0.7888
hsa-miR-7-5p	56.2 (260.4)	91.1 (347.0)	11.5 (19.9)	4.7 (11.8)	0.0362	0.2049	0.0275	0.1559	0.2616	0.6571
hsa-miR-376b-3p	14.6 (48.8)	19.0 (63.4)	9.0 (19.3)	1.1 (1.4)	0.3718	0.6213	0.2621	0.4951	0.7915	0.8751
hsa-miR-487b-3p	12.7 (56.4)	19.1 (75.0)	4.4 (10.2)	0.5 (0.7)	0.2437	0.6213	0.1181	0.2868	0.8237	0.8751
hsa-let-7f-1-3p	24.9 (114.7)	39.8 (153.0)	5.7 (9.4)	2.6 (2.8)	0.9893	0.9893	0.6856	0.8326	0.6496	0.7888
hsa-miR-500a-5p	55.8 (230.6)	94.7 (305.3)	5.7 (12.3)	1.7 (4.6)	0.3744	0.6213	0.4566	0.7056	0.4823	0.7416
hsa-miR-582-5p	144.8 (288.5)	208.4 (360.8)	63.0 (124.4)	31.5 (60.5)	0.0693	0.2946	0.0705	0.1998	0.2706	0.6571
miRNA Index (214, 7)	0.122 (0.332)	0.202 (0.430)	0.019 (0.034)	0.006 (0.013)	0.0010	0.0162	0.0005	0.0093	0.0732	0.6099

Average values of each group are shown. Standard deviations are shown in parenthesis. Differences were tested by Mann-Whitney's U test. To correct for multiple testing, the false discovery rate Q-value was calculated

RA rheumatoid arthritis, ILD interstitial lung disease, UIP Usual interstitial pneumonia, NSIP Nonspecific interstitial pneumonia, ILD(+)/RA RA with ILD, UIP(+)/RA RA with ILD of UIP pattern, NSIP(+)/RA RA with ILD of NSIP pattern, ILD(-)/RA RA without ILD

levels of miRNAs could not be detected in the present study (Additional file 5: Table S4). The effects of the biological DMARDs on the expression levels of miRNA were not found (Additional file 6: Table S5). For hsa-miR-214-5p, 135 target genes were predicted and include *SMAD4*, coding a protein involved in signal transduction of the transforming growth factor β [23]. For hsa-miR-7-5p, 434 target genes were predicted and include *BLOC1S4*. The mutation of *Bloc1s4* causes a model of Hermansky-Pudlak syndrome [24].

The area under the curve (AUC) value of the receiver operating characteristic (ROC) curve for hsa-miR-214-5p was 0.634 and that for hsa-miR-7-5p was 0.652 (Fig. 1c). Specificities and sensitivities of these miRNAs were estimated from the ROC curve conditional on the highest Youden's index. The optimized cut-off level of hsa-miR-214-5p was 0.429 with the sensitivity (0.375) and the specificity (0.906). The optimized cut-off level of hsa-miR-7-5p was 5.686 with the sensitivity (0.469) and the specificity (0.875).

An miRNA index (214, 7) was generated from the expression levels of hsa-miR-214-5p and hsa-miR-7-5p and evaluated as a marker for ILD(+)/RA; miRNA index (214, 7) = 0.0095 X hsa-miR-214-5p + 0.0008 X hsa-miR-7-5p. The miRNA index (214, 7) was higher in the ILD(+)/RA group (Fig. 1d, Table 2, $P = 0.0010$, $Q = 0.0162$, mean \pm SD = 0.122 \pm 0.332 in ILD(+)/RA, 0.006 \pm 0.013 in

ILD(-)/RA). The AUC value of the ROC curve for the miRNA index (214, 7) was 0.740 (Fig. 1e). Specificities and sensitivities of miRNA index (214, 7) were estimated from the ROC curve conditional on the highest Youden's index. The optimized cut-off level was 0.004 with the sensitivity (0.656) and specificity (0.813). Thus, the plasma miRNA profiles were different between ILD(+)/RA and ILD(-)/RA groups.

MiRNA expression profiles of RA patients with UIP or NSIP patterns

The expression levels of the 16 miRNAs were compared between the UIP(+)/RA and ILD(-)/RA. A tendency for the expression levels of hsa-miR-214-5p and hsa-miR-7-5p to be increased in the UIP(+)/RA group was also observed. The values of miRNA index (214, 7) in the UIP(+)/RA group was higher ($P = 0.0005$, $Q = 0.0093$, mean \pm SD = 0.202 \pm 0.430 in UIP(+)/RA). The expression pattern of the 16 miRNAs were also compared between the NSIP(+)/RA and ILD(-)/RA. No association was observed in the NSIP(+)/RA group. Thus, miRNA profiles were also altered in UIP(+)/RA groups.

Discussion

It was reported that plasma miRNA profiles are altered not only in cancerous patients [8–10], but also in patients with inflammatory diseases [11–15]. However, few




Fig. 1 Evaluation of the miRNA expression levels, as a marker for interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. **a** Distribution of the hsa-miR-214-5p. The filled square, filled circle, and empty circle represent RA without ILD, RA with usual interstitial pneumonia, and RA with nonspecific interstitial pneumonia, respectively. Horizontal bars denote means. The horizontal dotted line represents an optimized cut-off level (hsa-miR-214-5p = 0.429, with specificity and sensitivity of 0.906 and 0.375, respectively). ILD(+)-RA: RA with ILD, ILD(-)-RA: RA without ILD. **b** Distribution of the hsa-miR-7-5p. The horizontal dotted line represents an optimized cut-off level (hsa-miR-7-5p = 5.686, with specificity and sensitivity of 0.875 and 0.469, respectively). **c** The receiver operating characteristic (ROC) curve using the hsa-miR-214-5p (dotted line) and hsa-miR-7-5p (solid line) as markers for ILD in RA. The area under the curve (AUC) value of the ROC curve for hsa-miR-214-5p is 0.634 and that for hsa-miR-7-5p is 0.652. **d** Distribution of miRNA index (214, 7) generated from hsa-miR-214-5p and hsa-miR-7-5p for ILD ($=0.0095 \times \text{hsa-miR-214-5p} + 0.0008 \times \text{hsa-miR-7-5p}$). The horizontal dotted line represents an optimized cut-off level (miRNA index (214, 7) = 0.004, with specificity and sensitivity of 0.813 and 0.656, respectively). **e** The ROC curve using miRNA index (214, 7) as a marker for ILD in RA. The AUC value of the ROC curve is 0.740

studies have focused on miRNA profiling in RA-ILD, though these could be diagnostic markers overcoming the existing markers with low sensitivity [6, 7]. We have tried to discriminate RA-ILD, one of the potentially life-threatening extra-articular manifestations of RA, using plasma miRNA profiles. To the best of our knowledge, this is the first report of plasma miRNA profiles in RA-ILD. We found that hsa-miR-214-5p and hsa-miR-7-5p were increased in the ILD(+)-RA group (Fig. 1a and b), though the superiority of these miRNA profiles was not observed compared with KL-6 (AUC = 0.86, cut-off level = 331.5, sensitivity = 0.769, and specificity = 0.842) [7].

It was already well known that cancer cells produce circulating extracellular miRNAs in plasma samples from cancerous patients. Inflammatory cells or tissues may also produce circulating extracellular miRNAs in plasma samples from patients with inflammatory diseases. Thus, hsa-miR-214-5p and hsa-miR-7-5p might be

preferentially produced by inflammatory cells or tissues. Though the expression levels of hsa-miR-21 were increased in sera from IPF patients [14, 15, 17], this increase was not observed in the pooled sera from the ILD(+)-RA group (Additional file 1: Table S1). This discrepancy could be explained by the difference between the pathogenesis of IPF that includes only UIP and that of RA-ILD that includes both UIP and NSIP.

Since miRNAs modulate the expression of protein-coding genes at the post-transcription level, many studies on the expression and the function of miRNAs were reported. It was reported that the expression levels of hsa-miR-214-5p were increased in B cell lymphoma with better prognosis [25] and liver cirrhosis [26], but decreased in hepatocellular carcinoma [27]. The expression of hsa-miR-7-5p inhibits melanoma cell migration [28], and the decreased expression levels of hsa-miR-7-5p in follicular thyroid cancer were thought to be a reliable

marker [29]. The expression levels of hsa-miR-7-5p were increased in dental pulp stem cells [30]. The altered expression levels of hsa-miR-7-5p were also reported in breast cancer and glioblastoma [31–33]. Thus, the altered expression patterns and the function of hsa-miR-214-5p and hsa-miR-7-5p have been reported. The target genes of the two miRNAs were predicted. Although many genes were predicted, some predicted genes, including *SMAD4* and *BLOC1S4*, are known to be involved in the pathogenesis of ILD. However, further functional studies on these miRNAs would be expected to provide better understanding of the roles of these miRNA for the pathogenesis of RA-ILD.

Because of the limited sample size, the validation of miRNA profiles should be performed in future independent work. For the practical applications of miRNA biomarkers for RA-ILD, the expression patterns of all miRNAs should be comprehensively investigated. Therefore, further large-scale miRNA profiling using next generation sequencer could be expected.

Conclusions

This is the first report of plasma miRNA profiles of RA-ILD. The expression levels of hsa-miR-214-5p and hsa-miR-7-5p were increased in the ILD(+)RA group and they could be potential biomarkers for ILD in RA.

Additional files

Additional file 1: Table S1. miRNA expression ratios in plasmas from the RA patients with or without ILD. *Undefined Cvalues were substituted by 40. Selected miRNAs for further analyses were indicated in red. (DOCX 82 kb)

Additional file 2: Figure S1. Distribution of the miRNA, Krebs von den lungen-6 (KL-6), surfactant protein-D (SP-D), ILDIndex levels, as markers for interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. The filled square, filled circle, and empty circle represent ILD(-)RA, RA with usual interstitial pneumonia, and RA with nonspecific interstitial pneumonia, respectively. ILD(+)RA: RA with ILD, ILD(-)RA: RA without ILD. (TIFF 687 kb)

Additional file 3: Table S2. miRNA profiles of the RA patients with ILD. Standard deviations are shown in parenthesis. Difference were tested between male and female by Mann-Whitney's U test. RA: rheumatoid arthritis, ILD(+)RA: ILD positive RA. Average values of each group are shown. (DOCX 15 kb)

Additional file 4: Table S3. miRNA profiles of the RA patients with ILD. Average values of each group are shown. Standard deviations are shown in parenthesis. Difference were tested between age < 70 and age \geq 70 by Mann-Whitney's U test. RA: rheumatoid arthritis, ILD(+)RA: ILD positive RA. (DOCX 15 kb)

Additional file 5: Table S4. miRNA profiles of the RA patients with ILD. Average values of each group are shown. Standard deviations are shown in parenthesis. Difference were tested between DAS28 < 4.0 and DAS28 \geq 4.0 by Mann-Whitney's U test. RA: rheumatoid arthritis, ILD(+)RA: ILD positive RA. (DOCX 15 kb)

Additional file 6: Table S5. miRNA profiles of the RA patients with ILD. Average values of each group are shown. Standard deviations are shown in parenthesis. Difference were tested between bDMARDs(+) and bDMARDs(-) by Mann-Whitney's U test. RA: rheumatoid arthritis, ILD(+)RA: ILD positive RA. (DOCX 15 kb)

Abbreviations

AUC: Area under the curve; cDNA: Complementary DNA; CT: Computed tomography; HRCT: High resolution CT; ILD: Interstitial lung disease; ILD(+)RA: RA with ILD; ILD(-)RA: RA without ILD; IPF: Idiopathic pulmonary fibrosis; KL-6: Krebs von den lungen-6; miRNA: Micro RNA; NSIP: Nonspecific interstitial pneumonia; NSIP(+)RA: RA with ILD of NSIP pattern; RA: Rheumatoid arthritis; RA-ILD: RA-associated ILD; ROC: Receiver operating characteristic; SP-D: Surfactant protein-D; UIP: Usual interstitial pneumonia; UIP(+)RA: RA with ILD of UIP pattern

Acknowledgements

We thank Ms. Mayumi Yokoyama and Ms. Tomomi Hanawa (Clinical Research Center for Allergy and Rheumatology, Sagami Hospital) for secretarial assistance.

Funding

This study was supported by Grants-in-Aid for Scientific Research (B, C) (26293123, 15K09543), for Young Scientists (B) (24791018) from the Japan Society for the Promotion of Science, Health and Labour Science Research Grants from the Ministry of Health, Labour, and Welfare of Japan, Grants-in-Aid for Practical Research Project for Allergic Diseases and Immunology (Research on Allergic Diseases and Immunology) from Japan Agency for Medical Research and Development, Grants-in-Aid for Clinical Research from National Hospital Organization, Research Grants from Japan Research Foundation for Clinical Pharmacology, Research Grants from Takeda Science Foundation, Research Grants from Daiwa Securities Health Foundation, Research Grants from Mitsui Sumitomo Insurance Welfare Foundation, Research Grants from The Nakatomi Foundation, Bristol-Myers KK. RA Clinical Investigation Grant from Bristol-Myers Squibb Co., and research grants from the following pharmaceutical companies: Teijin Pharma Limited, Takeda Pharmaceutical Company Limited, Pfizer Japan Inc., Merck Sharp and Dohme Inc., Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., Abbott Japan Co., Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparing the manuscript.

Availability of data and materials

All the data were presented in the main text and additional supporting files. The data obtained from the microRNA PCR panels were deposited in Gene Expression Omnibus of National Center for Biotechnology Information and are accessible by accession number GSE88899.

Authors' contributions

HF, NT, and ST conceived and designed the experiments. SO and HF performed the experiments. HF analyzed the data. HF, KS, AH, AK, NF, and ST contributed reagents/materials/analysis tools. SO, HF, NT, and ST wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies; Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co., Ltd, the Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc., the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company, the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc., and the Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo. HF received honoraria from Ajinomoto Co., Inc., Ayumi Pharmaceutical Corporation, Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., Luminex Corporation, and Takeda Pharmaceutical Company. NT is supported by SENSHIN Medical Research Foundation, which is supported by an endowment from Mitsubishi Tanabe Pharma Corporation, and received honoraria from Asahi Kasei Corporation, Eisai Co., Ltd., Daiichi Sankyo Co., Ltd. ST was supported by research grants from pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited. ST received honoraria from Pfizer Japan Inc, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., AbbVie GK, Astellas Pharma Inc., Asahi Kasei Pharma Corporation. The other authors declare no financial or commercial conflict of interest.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was reviewed and approved by Sagami Hospital Research Ethics Committee and University of Tsukuba Research Ethics Committee. Written informed consent was obtained from all study participants.

Author details

¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan. ²Clinical Research Center for Allergy and Rheumatology, Sagami Hospital, National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagami-hara 252-0392, Japan. ³Department of Rheumatology, Sagami-hara Hospital, National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagami-hara 252-0392, Japan. ⁴Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashi-dai, Fuchu 183-8524, Japan.

Received: 7 June 2016 Accepted: 4 January 2017

Published online: 19 January 2017

References

- Furukawa H, Oka S, Shimada K, Sugii S, Ohashi J, Matsui T, Ikenaka T, Nakayama H, Hashimoto A, Takaoka H, et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: A protective role for shared epitope. *PLoS One*. 2012;7(5):e33133.
- Mori S, Cho I, Koga Y, Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. *J Rheumatol*. 2008;35(8):1513–21.
- Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman 3rd RL, Paine R, Flint A, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. *Eur Respir J*. 2002;19(2):275–83.
- Turesson C, Jacobsson L, Bergstrom U, Truedsson L, Sturfelt G. Predictors of extra-articular manifestations in rheumatoid arthritis. *Scand J Rheumatol*. 2000;29(6):358–64.
- Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, Dixey J, Gough A, Prouse P, Winfield J, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. *Rheumatology*. 2010; 49(8):1483–9.
- Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. *Am J Respir Crit Care Med*. 2002;165(3):378–81.
- Furukawa H, Oka S, Takehana K, Muramatsu T, Shimada K, Komiya A, Fukui N, Tsuchiya N, Tohma S. Plasma amino acid profiles in collagen disease patients with interstitial lung disease. *Immunome Res*. 2013;9(1):1000064.
- Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. *Gut*. 2009;58(10):1375–81.
- Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *Int J Cancer*. 2010;127(1):118–26.
- Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. *Cancer J*. 2012;18(3):244–52.
- Duroux-Richard I, Jorgensen C, Apparailly F. What do microRNAs mean for rheumatoid arthritis? *Arthritis Rheum*. 2012;64(1):11–20.
- Murata K, Furu M, Yoshitomi H, Ishikawa M, Shibuya H, Hashimoto M, Imura Y, Fujii T, Ito H, Mimori T, et al. Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. *PLoS One*. 2013;8(7):e69118.
- Wu F, Guo NJ, Tian H, Marohn M, Gearhart S, Bayless TM, Brant SR, Kwon JH. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease. *Inflamm Bowel Dis*. 2011;17(1):241–50.
- Li P, Li J, Chen T, Wang H, Chu H, Chang J, Zang W, Wang Y, Ma Y, Du Y, et al. Expression analysis of serum microRNAs in idiopathic pulmonary fibrosis. *Int J Mol Med*. 2014;33(6):1554–62.
- Yang G, Yang L, Wang W, Wang J, Xu Z. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression. *Gene*. 2015;562(1):138–44.
- Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. *Arthritis Res Ther*. 2010;12(3):R86.
- Li P, Zhao GQ, Chen TF, Chang JX, Wang HQ, Chen SS, Zhang GJ. Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis. *J Asthma*. 2013;50(9):960–4.
- Tanaka N, Kim JS, Newell JD, Brown KK, Cool CD, Meehan R, Emoto T, Matsumoto T, Lynch DA. Rheumatoid arthritis-related lung diseases: CT findings. *Radiology*. 2004;232(1):81–91.
- Oka S, Furukawa H, Shimada K, Sugii S, Hashimoto A, Komiya A, Fukui N, Suda A, Tsunoda S, Ito S, et al. Association of human leukocyte antigen alleles with chronic lung diseases in rheumatoid arthritis. *Rheumatology (Oxford)*. 2016. in press.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*. 1988;31(3):315–24.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc B*. 1995;57(1):289–300.
- Wang X. Improving microRNA target prediction by modeling with unambiguously identified microRNA-target pairs from CLIP-Ligation studies. *Bioinformatics*. 2016;2016:6.
- Shioda T, Lechleider RJ, Dunwoodie SL, Li H, Yahata T, de Caestecker MP, Fenner MH, Roberts AB, Isselbacher KJ. Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivator. *Proc Natl Acad Sci U S A*. 1998;95(17):9785–90.
- Ciciotte SL, Gwynn B, Moriyama K, Huizinga M, Gahl WA, Bonifacio JS, Peters LL. Cappuccino, a mouse model of Hermansky-Pudlak syndrome, encodes a novel protein that is part of the pallidin-muted complex (BLOC-1). *Blood*. 2003;101(11):4402–7.
- Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, et al. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. *Genome Biol*. 2015;16(18):18.
- Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, Kawada N. Induction of microRNA-214-5p in human and rodent liver fibrosis. *Fibrogenesis Tissue Repair*. 2012;5(1):12.
- Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciag M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L, Niewinski G, et al. Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. *Int J Biochem Cell Biol*. 2014;53:208–17.
- Giles KM, Brown RA, Epis MR, Kalinowski FC, Leedman PJ. miRNA-7-5p inhibits melanoma cell migration and invasion. *Biochem Biophys Res Commun*. 2013;430(2):706–10.
- Stokowy T, Wojtas B, Fajarsiewicz K, Jarzab B, Eszlinger M, Paschke R. miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis. *Horm Metab Res*. 2013; 46(3):171–80.
- Vasanthan P, Govindasamy V, Gnanasegaran N, Kunasekaran W, Musa S, Abu Kasim NH. Differential expression of basal microRNAs' patterns in human dental pulp stem cells. *J Cell Mol Med*. 2015;19(3):566–80.
- Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, Filassi JR, Baracat EC. Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. *Tumour Biol*. 2014;35(8):7733–41.
- Liu Z, Liu Y, Li L, Xu Z, Bi B, Wang Y, Li JY. miR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1. *Tumour Biol*. 2014;35(10):10177–84.
- Dong L, Li Y, Han C, Wang X, She L, Zhang H. miRNA microarray reveals specific expression in the peripheral blood of glioblastoma patients. *Int J Oncol*. 2014;45(2):746–56.